Premium
TriSalus Life Sciences Inc (TLSI)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year – Provided 2025 guidance with expectations of over 50% annual sales growth...
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients suffering from liver cancer through its advanced...
TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to transform treatment for liver and...
Call Scheduled for Thursday, November 14, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and...
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced...
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced...
Pressure enabled drug deliver (PEDD) method significantly increased penetration of glass microspheres into porcine liver tumors (117%; p=0.004 and 39%; p=0.032) with lobar infusions and selective...
Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to prior year periods Reported gross margin of 88% in Q2...
Call Scheduled for Thursday, August 15, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to...
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.12 | 2.44897959184 | 4.9 | 5.1802 | 4.77 | 37232 | 4.92393199 | CS |
| 4 | 0.85 | 20.3836930456 | 4.17 | 5.43 | 3.5 | 42804 | 4.37088573 | CS |
| 12 | 0.74 | 17.2897196262 | 4.28 | 5.43 | 3.5 | 38732 | 4.253414 | CS |
| 26 | 0.02 | 0.4 | 5 | 6.04 | 3.5 | 41820 | 4.75729597 | CS |
| 52 | -3.23 | -39.1515151515 | 8.25 | 10.42 | 3.5 | 39707 | 6.5765371 | CS |
| 156 | -8.78 | -63.6231884058 | 13.8 | 16.24 | 3.32 | 47992 | 6.58968521 | CS |
| 260 | -8.78 | -63.6231884058 | 13.8 | 16.24 | 3.32 | 47992 | 6.58968521 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
